ArticleCureus2026
Clobazam in Adult Drug-Resistant Epilepsy: Excellent Long-Term Retention and Potential Synergy with Neuromodulation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clobazam in pediatric drug-resistant epilepsy: from pharmacology to clinical practice.European journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug-resistant epilepsy (DRE) is a major clinical challenge. While clobazam, a 1,5-benzodiazepine, is an effective adjunctive therapy, concerns regarding tolerability and discontinuation rates have been reported in some studies. This study evaluates the long-term efficacy and tolerability specifically among adults with DRE who successfully tolerated at least six months of clobazam treatment at a Level 4 Epilepsy Center, providing insights into outcomes in treatment-tolerant patients. METHODOLOGY: A single-center retrospective chart review was conducted of 160 adult patients with DRE treated with clobazam for at least six months at a Level 4 Epilepsy Center. Data on seizure frequency, clobazam dosage, tolerability, and concomitant therapies, including neuromodulation devices, were analyzed.
resultsThe cohort (
conclusionsAmong adults with DRE who successfully tolerate at least six months of clobazam therapy, long-term retention is excellent (95%), and sustained efficacy is maintained. These findings provide valuable insight into long-term outcomes, specifically in treatment-tolerant patients. Furthermore, combination therapy with neuromodulation demonstrates potential complementarity. These findings provide valuable insight into long-term outcomes in treatment-tolerant patients and suggest that careful ongoing management optimizes clinical outcomes in adult DRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.